148 related articles for article (PubMed ID: 16619218)
1. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
Roelofs AJ; Hulley PA; Meijer A; Ebetino FH; Russell RG; Shipman CM
Int J Cancer; 2006 Sep; 119(6):1254-61. PubMed ID: 16619218
[TBL] [Abstract][Full Text] [Related]
2. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
3. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Lawson MA; Coulton L; Ebetino FH; Vanderkerken K; Croucher PI
Biochem Biophys Res Commun; 2008 Dec; 377(2):453-457. PubMed ID: 18929536
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
Marma MS; Xia Z; Stewart C; Coxon F; Dunford JE; Baron R; Kashemirov BA; Ebetino FH; Triffitt JT; Russell RG; McKenna CE
J Med Chem; 2007 Nov; 50(24):5967-75. PubMed ID: 17975902
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
McKenna CE; Kashemirov BA; Błazewska KM; Mallard-Favier I; Stewart CA; Rojas J; Lundy MW; Ebetino FH; Baron RA; Dunford JE; Kirsten ML; Seabra MC; Bala JL; Marma MS; Rogers MJ; Coxon FP
J Med Chem; 2010 May; 53(9):3454-64. PubMed ID: 20394422
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.
Coxon FP; Helfrich MH; Larijani B; Muzylak M; Dunford JE; Marshall D; McKinnon AD; Nesbitt SA; Horton MA; Seabra MC; Ebetino FH; Rogers MJ
J Biol Chem; 2001 Dec; 276(51):48213-22. PubMed ID: 11581260
[TBL] [Abstract][Full Text] [Related]
7. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid produces antitumor effects on mesothelioma through apoptosis and S-phase arrest in p53-independent and Ras prenylation-independent manners.
Okamoto S; Kawamura K; Li Q; Yamanaka M; Yang S; Fukamachi T; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Kobayashi H; Tagawa M
J Thorac Oncol; 2012 May; 7(5):873-82. PubMed ID: 22481236
[TBL] [Abstract][Full Text] [Related]
12. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
[TBL] [Abstract][Full Text] [Related]
13. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Guenther A; Gordon S; Tiemann M; Burger R; Bakker F; Green JR; Baum W; Roelofs AJ; Rogers MJ; Gramatzki M
Int J Cancer; 2010 Jan; 126(1):239-46. PubMed ID: 19621390
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
[TBL] [Abstract][Full Text] [Related]
15. Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells.
Fujita H; Kurokawa K; Ogino T; Ono M; Yamamoto M; Oka T; Nakanishi T; Kobayashi N; Tanaka N; Ogawa T; Suzaki E; Utsumi K; Sasaki J
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):78-84. PubMed ID: 21332944
[TBL] [Abstract][Full Text] [Related]
16. Shotgun proteomics analysis reveals new unsuspected molecular effectors of nitrogen-containing bisphosphonates in osteocytes.
Bivi N; Picotti P; Müller LN; Romanello M; Moro L; Quadrifoglio F; Tell G
J Proteomics; 2011 Jun; 74(7):1113-22. PubMed ID: 21504803
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
18. The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates.
Coxon FP; Taylor A; Stewart CA; Baron R; Seabra MC; Ebetino FH; Rogers MJ
Bone; 2011 Jul; 49(1):111-21. PubMed ID: 21419243
[TBL] [Abstract][Full Text] [Related]
19. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
20. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
